Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Abbott Announces Future of Biowearables at Consumer Electronics Show
Making CES history, Abbott (NYSE: ABT) presented a keynote at the most influential tech event in the world, […]
Abbott's New Leadless Pacemaker System Meets Primary Endpoints in Pivotal Trial
Abbott (NYSE: ABT) today announced new, late-breaking data from the global Leadless II IDE study evaluating […]
Abbott Expands with Acquisition of Walk Vascular, LLC
Abbott (NYSE: ABT) announced today that it has acquired Walk Vascular, LLC, a commercial-stage medical device company with […]
Abbott Confirms Capacity to Support Expanded Use of HeartMate 3™ Heart Pump
Abbott today announced the company has capacity and supply to effectively support the growing demand […]
Abbott New Trial Seeks Better Treatment for AFib and Heart Failure
Abbott (NYSE: ABT) today announced a new trial focused on improving the treatment for people simultaneously […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more